Newswise — PHILADELPHIA (January 19, 2022) – It is not uncommon for people with opioid-related conditions, including opioid dependence and opioid use disorder (OUD), to be regularly hospitalized to treat infections, trauma, or other emergent conditions. Data show that patients with substance use disorders (SUD) are much more likely to self-discharge against medical advice than patients admitted for similar conditions without SUDs. This can lead to poorer health outcomes including worsening illness, readmissions, and death.
Could poorly treated pain be a reason for these self-directed discharges, and if so, what approaches could be tried to prevent patients who have been historically marginalized from experiencing avoidable harm and suffering?
A new study from the University of Pennsylvania School of Nursing (Penn Nursing) published in the Harm Reduction Journal suggests that stigma toward persons with SUDs, including OUD, may account for an under assessment and management of pain.
The study found that patients with acutely painful admitting diagnoses were almost twice as likely to have a self-directed discharge than those without. These diagnosis codes were extremely common among patients who had a self-directed discharge on six or more occasions within a single year. The study also found that a diagnosis of chronic pain was inconsistently noted in the patient group, leading to the conclusion that inadequate pain assessment is a potential motivator of self-directed discharge in this patient population.
“These findings underscore the importance of pain care in disrupting a process of self-directed discharge, intensifying harm, and preventable financial costs and suffering,” says lead author of the article Peggy Compton, PHD, RN, FAAN, van Ameringen Chair in Psychiatric and Mental Health Nursing and Professor of Nursing at Penn Nursing. “Each admission represents a potential opportunity to provide harm reduction and treatment interventions addressing both substance use and pain.”
The article “Acute Pain and Self-Directed Discharge Among Hospitalized Patients with Opioid-Related Diagnoses: A Cohort Study” is available online. Co-authors of the article are Penn Nursing’s Shoshana V. Aronowtiz, PhD, MSHP, FNP-BC, Assistant Professor, Department of Family and Community Health; Evan Anderson, JD, PhD, Lecturer, Department of Biobehavioral Health Sciences; and Penn Medicine’s Heather Klusaritz.
The study was in part supported by funding from the National Institutes on Drug Abuse [R21 DA046364 (P.C.)], the National Institute of Nursing [R21 NR019047 (P.C.)], and training grant support from the National Clinician Scholars Program (S.V.A).
# # #
About the University of Pennsylvania School of Nursing
The University of Pennsylvania School of Nursing is one of the world’s leading schools of nursing. For the sixth year in a row, it is ranked the #1 nursing school in the world by QS University. In a first for any undergraduate Bachelor of Science in Nursing (BSN) program in the country, our BSN program is ranked # 1 in the 2022 U.S. News & World Report’s Best Colleges rankings. Penn Nursing is also consistently ranked highly in the U.S. News & World Report annual list of best graduate schools and is ranked as one of the top schools of nursing in funding from the National Institutes of Health. Penn Nursing prepares nurse scientists and nurse leaders to meet the health needs of a global society through innovation in research, education, and practice. Follow Penn Nursing on: Facebook, Twitter, LinkedIn, & Instagram.
MEDIA CONTACT
Register for reporter access to contact detailsCITATIONS
Harm Reduction Journal; R21 DA046364; R21 NR019047